Central Sympatholytics Prolong Survival in Experimental Sepsis
Overview
Authors
Affiliations
Introduction: One of the main causes of death in European and US intensive care units is sepsis. It involves a network of pro-inflammatory cytokines such as TNF-alpha, IL-1beta and IL-6. Furthermore, there is an up regulation of transcription factors such as nuclear factor (NF) kappaB. It has previously been shown that clonidine is able to significantly reduce pro-inflammatory cytokines in surgical patients. We therefore hypothesise that the clinically used central alpha-2 agonist clonidine has the ability to improve survival in experimental sepsis by inhibiting the sympathetic tone and consequently inhibiting the pro-inflammatory cytokine release.
Methods: To investigate this therapeutic potential of clonidine in a prospective randomised laboratory investigation we used a murine model of caecal ligation and puncture (CLP) induced sepsis. Animals receiving pre-emptive injections were treated with either clonidine (5 microg/kg) or dexmedetomidine (40 microg/kg) 12 and 1 hours before the operation, as well as 1, 6 and 12 hours afterwards. Another group of animals only received clonidine (5 microg/kg) 1, 6 and 12 hours after the operation, while the pre-emptive injections were normal saline. The control groups received solvent injections at the respective time points.
Results: Pre-emptive administration of a central sympatholytic significantly reduced mortality (clonidine: p = 0.015; dexmedetomidine: p = 0.029), although postoperative administration of clonidine failed to significantly prolong survival. Furthermore pre-emptive administration of clonidine significantly attenuated the cytokine response after CLP-induced sepsis (mIL-1beta: p = 0.017; mIL-6: p < 0.0001; mTNF-alpha: p < 0.0001), preserved blood pressure control (p = 0.024) and down-regulated the binding activity of NF-kappaB. There were no changes in the pro-inflammatory cytokine response when peripheral blood was incubated with lipopolysaccharide alone compared with incubation with clonidine (10-4 M) plus LPS (p > 0.05).
Conclusions: Our results demonstrate that the pre-emptive administration of either clonidine or dexmedetomidine have the ability to successfully improve survival in experimental sepsis. Furthermore, there seems to be a connection between the central muscarinic network and the vagal cholinergic response. By down-regulating pro-inflammatory mediators sympatholytics may be a useful adjunct sedative in patients with a high risk for developing sepsis.
Jia Z, Kong L, Lu X, Lu J, Shen Y, Qiao Z BMC Gastroenterol. 2024; 24(1):407.
PMID: 39538196 PMC: 11558820. DOI: 10.1186/s12876-024-03498-z.
Peng J, Wu Y, Li L, Xia P, Yu P, Zhang J Front Cardiovasc Med. 2024; 11:1433841.
PMID: 39450236 PMC: 11499117. DOI: 10.3389/fcvm.2024.1433841.
Vascular leak in sepsis: physiological basis and potential therapeutic advances.
McMullan R, McAuley D, OKane C, Silversides J Crit Care. 2024; 28(1):97.
PMID: 38521954 PMC: 10961003. DOI: 10.1186/s13054-024-04875-6.
Luo X, Chen P, Chang X, Li Y, Wan L, Xue F J Clin Med. 2023; 12(5).
PMID: 36902603 PMC: 10003055. DOI: 10.3390/jcm12051816.
Bo J, Wang J, Wang X, Jiao Y, Jiang M, Chen J Antioxidants (Basel). 2022; 11(12).
PMID: 36552603 PMC: 9774688. DOI: 10.3390/antiox11122395.